PL399138A1 - Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego - Google Patents

Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Info

Publication number: PL399138A1
Authority: PL; Poland
Prior art keywords: peptide; pharmaceutical composition; tolerogenic; administration; application
Prior art date: 2000-08-21

Application number

PL399138A

Other languages

English (en)

Other versions

PL215145B1 (pl

Inventor

Stephen Mark Anderton

Graziella Mazza

Mary Ponsford

Heather Barbara Streeter

David Cameron Wraith

Original Assignee

Apitope Technology (Bristol) Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-21

Filing date

2001-08-17

Publication date

2012-07-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL399138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-21 Priority claimed from GB0020618A external-priority patent/GB0020618D0/en

2001-06-14 Priority claimed from GB0114547A external-priority patent/GB0114547D0/en

2001-08-17 Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited

2012-07-30 Publication of PL399138A1 publication Critical patent/PL399138A1/pl

2013-10-31 Publication of PL215145B1 publication Critical patent/PL215145B1/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Rehabilitation Therapy (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)

PL399138A 2000-08-21 2001-08-17 Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego PL215145B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0020618A GB0020618D0 (en)	2000-08-21	2000-08-21	Peptide selection method
GB0114547A GB0114547D0 (en)	2001-06-14	2001-06-14	Peptide selection method

Publications (2)

Publication Number	Publication Date
PL399138A1 true PL399138A1 (pl)	2012-07-30
PL215145B1 PL215145B1 (pl)	2013-10-31

Family

ID=26244875

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL399137A PL215187B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL399138A PL215145B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
PL364048A PL217929B1 (pl)	2000-08-21	2001-08-17	Sposób wyboru in vitro peptydu przydatnego w zapobieganiu i/lub leczeniu chorób z nadmiernym uczuleniem
PL395781A PL213585B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL399137A PL215187B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL364048A PL217929B1 (pl)	2000-08-21	2001-08-17	Sposób wyboru in vitro peptydu przydatnego w zapobieganiu i/lub leczeniu chorób z nadmiernym uczuleniem
PL395781A PL213585B1 (pl)	2000-08-21	2001-08-17	Peptyd tolerogenny, kompozycja farmaceutyczna zawierajaca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego

Country Status (25)

Country	Link
US (4)	US20030191063A1 (pl)
EP (3)	EP1918298B1 (pl)
JP (1)	JP5431628B2 (pl)
KR (1)	KR20030062321A (pl)
CN (4)	CN102784385B (pl)
AT (2)	ATE483729T1 (pl)
AU (2)	AU2001278637B2 (pl)
BR (2)	BRPI0113400B1 (pl)
CA (1)	CA2420949C (pl)
CY (3)	CY1108558T1 (pl)
CZ (1)	CZ307202B6 (pl)
DE (2)	DE60143234D1 (pl)
DK (3)	DK1731912T3 (pl)
ES (3)	ES2439899T3 (pl)
HK (3)	HK1052359B (pl)
HU (3)	HU230233B1 (pl)
IL (1)	IL154089A0 (pl)
MX (1)	MXPA03001606A (pl)
NO (2)	NO330535B1 (pl)
NZ (1)	NZ523841A (pl)
PH (1)	PH12013500208B1 (pl)
PL (4)	PL215187B1 (pl)
PT (3)	PT1918298E (pl)
SI (3)	SI1918298T1 (pl)
WO (1)	WO2002016410A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030191063A1 (en)	2000-08-21	2003-10-09	Wraith David Cameron	Peptide selection method
GB0202399D0 (en) *	2002-02-01	2002-03-20	Univ Bristol	Peptide
WO2007131210A2 (en) *	2006-05-05	2007-11-15	Opexa Therapeutics	T-cell vaccine
GB0710529D0 (en)	2007-06-01	2007-07-11	Circassia Ltd	Vaccine
AU2008288283B2 (en)	2007-08-15	2013-01-31	Circassia Limited	Peptides for desensibilization against allergens
CA2703170C (en) *	2007-10-31	2016-10-11	Apitope Technology (Bristol) Limited	Composition comprising myelin basic proteins
GB0723712D0 (en) *	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides
ITMI20080508A1 (it) *	2008-03-27	2009-09-28	Istituto Nazionale Di Genetica Molecolare	Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) *	2008-05-13	2009-11-14	Istituto Naz Di Genetica Molecolare Ingm	Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
US9085798B2 (en)	2009-04-30	2015-07-21	Prognosys Biosciences, Inc.	Nucleic acid constructs and methods of use
GB0908515D0 (en)	2009-05-18	2009-06-24	Apitope Technology Bristol Ltd	Peptide
MX2012004295A (es)	2009-10-12	2012-08-15	Lifebio Lab Llc	Composicion para el tratamiento de esclerosis multiple.
RU2448685C2 (ru) *	2009-11-30	2012-04-27	Российская Федерация в лице Министерства промышленности и торговли Российской Федерации	Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
AU2011237729B2 (en)	2010-04-05	2014-04-03	Prognosys Biosciences, Inc.	Spatially encoded biological assays
US20190300945A1 (en)	2010-04-05	2019-10-03	Prognosys Biosciences, Inc.	Spatially Encoded Biological Assays
US10787701B2 (en)	2010-04-05	2020-09-29	Prognosys Biosciences, Inc.	Spatially encoded biological assays
KR200457779Y1 (ko) *	2010-06-23	2012-01-06	이준혁	샤프펜슬
EP2694709B1 (en)	2011-04-08	2016-09-14	Prognosys Biosciences, Inc.	Peptide constructs and assay systems
GB201106254D0 (en)	2011-04-13	2011-05-25	Frisen Jonas	Method and product
PL397623A1 (pl) *	2011-12-30	2013-07-08	Napco S. Ar.L.	Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
EP3511423B2 (en)	2012-10-17	2024-05-29	Spatial Transcriptomics AB	Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
PL2917232T3 (pl)	2012-11-12	2017-09-29	Apitope International Nv	Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
EP3736573A1 (en)	2013-03-15	2020-11-11	Prognosys Biosciences, Inc.	Methods for detecting peptide/mhc/tcr binding
CA2916662C (en)	2013-06-25	2022-03-08	Prognosys Biosciences, Inc.	Methods and systems for determining spatial patterns of biological targets in a sample
GB201314052D0 (en) *	2013-08-06	2013-09-18	Apitope Int Nv	Peptides
US10288608B2 (en)	2013-11-08	2019-05-14	Prognosys Biosciences, Inc.	Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko)	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN107249617A (zh)	2014-12-24	2017-10-13	艾匹托普国际股份有限公司	组合物
CA2982146A1 (en)	2015-04-10	2016-10-13	Spatial Transcriptomics Ab	Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US12139526B2 (en)	2015-12-03	2024-11-12	Juno Therapeutics, Inc.	Modified chimeric receptors and related compositions and methods
GB201700095D0 (en) *	2017-01-04	2017-02-22	Apitope Int Nv	Composition
CA3049182A1 (en) *	2017-01-04	2018-07-12	Apitope Technology (Bristol) Limited	S-arrestin peptides and therapeutic uses thereof
US20200046802A1 (en) *	2017-01-04	2020-02-13	Apitope International Nv	Therapeutic method using tolerogenic peptides
EP3523332B1 (en)	2017-01-06	2021-12-29	Eutilex Co., Ltd.	Anti-human 4-1 bb antibodies and use thereof
GB201909774D0 (en)	2019-07-08	2019-08-21	Apitope Tech Bristol Limited	Method
RU2761617C2 (ru) *	2019-10-04	2021-12-13	Жаудат Гафурович Умеров	Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
US20210190770A1 (en)	2019-12-23	2021-06-24	10X Genomics, Inc.	Compositions and methods for using fixed biological samples in partition-based assays
GB201919222D0 (en)	2019-12-23	2020-02-05	Apitope Int Nv	Composition
TR201922305A2 (tr) *	2019-12-30	2021-07-26	T C Erciyes Ueniversitesi	Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11702693B2 (en)	2020-01-21	2023-07-18	10X Genomics, Inc.	Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en)	2020-01-21	2023-08-22	10X Genomics, Inc.	Spatial assays with perturbed cells
US11835462B2 (en)	2020-02-11	2023-12-05	10X Genomics, Inc.	Methods and compositions for partitioning a biological sample
US11926863B1 (en)	2020-02-27	2024-03-12	10X Genomics, Inc.	Solid state single cell method for analyzing fixed biological cells
WO2021144478A2 (en)	2020-05-06	2021-07-22	Imcyse Sa	Combination treatment for fumarate-related diseases
WO2021236929A1 (en)	2020-05-22	2021-11-25	10X Genomics, Inc.	Simultaneous spatio-temporal measurement of gene expression and cellular activity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1327162C (en)	1987-04-09	1994-02-22	Board Of Trustees Of The Leland Stanford Junior University (The)	Method for prophylactically treating an individual for an autoimmune disease
AU632991B2 (en)	1987-06-24	1993-01-21	Autoimmune, Inc.	Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) *	1988-06-23	1993-11-09	Anergen, Inc.	MHC conjugates useful in ameliorating autoimmunity
US5858980A (en) *	1990-03-30	1999-01-12	Autoimmune, Inc.	Peptide fragments of myelin basic protein
IL165071A (en) *	1990-03-30	2008-06-05	Autoimmune Inc	A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5593698A (en)	1990-10-31	1997-01-14	Autoimmune, Inc.	Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) *	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en)	1993-01-29	1999-11-23	University Of Pittsburgh	Elution and identification of T cell epitopes from viable cells
HUT76099A (en) *	1994-05-10	1997-06-30	Immulogic Pharma Corp	Compositions and treatment for multiple sclerosis
AU7242994A (en)	1994-05-20	1995-12-18	United States Of America, As Represented By The Secretary Of The Army, The	Model for testing immunogenicity of peptides
US6251396B1 (en) *	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) *	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en) *	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996032957A1 (en) *	1995-04-20	1996-10-24	Brigham & Women's Hospital	Modulation of cytokine patterns of human autoreactive t-cell clones
WO1997041440A1 (en) *	1996-04-26	1997-11-06	Rijksuniversiteit Te Leiden	Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
EP0849275A1 (en) *	1996-09-26	1998-06-24	Rijksuniversiteit te Leiden	Mannosylated peptides
EP1085892A4 (en)	1998-06-12	2002-07-17	Sloan Kettering Inst Cancer	VACCINATION STRATEGY FOR PREVENTING AND TREATING CANCERS
MY129566A (en) *	1999-01-19	2007-04-30	Nestle Sa	A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US20030191063A1 (en) *	2000-08-21	2003-10-09	Wraith David Cameron	Peptide selection method
GB0202399D0 (en)	2002-02-01	2002-03-20	Univ Bristol	Peptide
US8314290B2 (en)	2004-12-21	2012-11-20	Monsanto Technology Llc	Temporal regulation of gene expression by MicroRNAs
CA2703170C (en) *	2007-10-31	2016-10-11	Apitope Technology (Bristol) Limited	Composition comprising myelin basic proteins
GB0723712D0 (en)	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides

2001
- 2001-08-17 US US10/362,264 patent/US20030191063A1/en not_active Abandoned
- 2001-08-17 PL PL399137A patent/PL215187B1/pl unknown
- 2001-08-17 DE DE60143234T patent/DE60143234D1/de not_active Expired - Lifetime
- 2001-08-17 DK DK06014901.0T patent/DK1731912T3/da active
- 2001-08-17 KR KR10-2003-7002514A patent/KR20030062321A/ko not_active Application Discontinuation
- 2001-08-17 SI SI200130983T patent/SI1918298T1/sl unknown
- 2001-08-17 AT AT08002817T patent/ATE483729T1/de active
- 2001-08-17 DE DE60134862T patent/DE60134862D1/de not_active Expired - Lifetime
- 2001-08-17 BR BRPI0113400-0A patent/BRPI0113400B1/pt unknown
- 2001-08-17 WO PCT/GB2001/003702 patent/WO2002016410A2/en active Application Filing
- 2001-08-17 AU AU2001278637A patent/AU2001278637B2/en not_active Ceased
- 2001-08-17 PL PL399138A patent/PL215145B1/pl unknown
- 2001-08-17 PL PL364048A patent/PL217929B1/pl unknown
- 2001-08-17 AU AU7863701A patent/AU7863701A/xx active Pending
- 2001-08-17 BR BR0113400-0A patent/BR0113400A/pt not_active IP Right Cessation
- 2001-08-17 EP EP08002817A patent/EP1918298B1/en not_active Expired - Lifetime
- 2001-08-17 AT AT01956718T patent/ATE401343T1/de active
- 2001-08-17 EP EP06014901.0A patent/EP1731912B1/en not_active Expired - Lifetime
- 2001-08-17 IL IL15408901A patent/IL154089A0/xx unknown
- 2001-08-17 CN CN201210156674.1A patent/CN102784385B/zh not_active Expired - Fee Related
- 2001-08-17 PT PT08002817T patent/PT1918298E/pt unknown
- 2001-08-17 CN CN2009101296721A patent/CN101633689B/zh not_active Expired - Fee Related
- 2001-08-17 DK DK08002817.8T patent/DK1918298T3/da active
- 2001-08-17 ES ES06014901.0T patent/ES2439899T3/es not_active Expired - Lifetime
- 2001-08-17 CN CN201210156712.3A patent/CN102764425B/zh not_active Expired - Fee Related
- 2001-08-17 ES ES08002817T patent/ES2353347T3/es not_active Expired - Lifetime
- 2001-08-17 PT PT60149010T patent/PT1731912E/pt unknown
- 2001-08-17 SI SI200131032T patent/SI1731912T1/sl unknown
- 2001-08-17 EP EP01956718A patent/EP1311542B1/en not_active Expired - Lifetime
- 2001-08-17 SI SI200130860T patent/SI1311542T1/sl unknown
- 2001-08-17 DK DK01956718T patent/DK1311542T3/da active
- 2001-08-17 HU HU1300358A patent/HU230233B1/hu not_active IP Right Cessation
- 2001-08-17 CN CNA018176828A patent/CN1469883A/zh active Pending
- 2001-08-17 PL PL395781A patent/PL213585B1/pl unknown
- 2001-08-17 JP JP2002521505A patent/JP5431628B2/ja not_active Expired - Fee Related
- 2001-08-17 ES ES01956718T patent/ES2310558T3/es not_active Expired - Lifetime
- 2001-08-17 CA CA2420949A patent/CA2420949C/en not_active Expired - Lifetime
- 2001-08-17 HU HU0300814A patent/HU229489B1/hu not_active IP Right Cessation
- 2001-08-17 MX MXPA03001606A patent/MXPA03001606A/es active IP Right Grant
- 2001-08-17 CZ CZ2003-512A patent/CZ307202B6/cs not_active IP Right Cessation
- 2001-08-17 HU HU1300357A patent/HU229377B1/hu not_active IP Right Cessation
- 2001-08-17 NZ NZ523841A patent/NZ523841A/en not_active IP Right Cessation
- 2001-08-17 PT PT01956718T patent/PT1311542E/pt unknown
2003
- 2003-02-19 NO NO20030790A patent/NO330535B1/no not_active IP Right Cessation
- 2003-06-26 HK HK03104592.1A patent/HK1052359B/zh not_active IP Right Cessation
2007
- 2007-10-31 US US11/979,224 patent/US8343500B2/en not_active Expired - Fee Related
2008
- 2008-10-13 CY CY20081101132T patent/CY1108558T1/el unknown
2010
- 2010-10-18 NO NO20101441A patent/NO337988B1/no not_active IP Right Cessation
2011
- 2011-01-04 CY CY20111100017T patent/CY1111079T1/el unknown
2012
- 2012-12-06 US US13/706,540 patent/US8961986B2/en not_active Expired - Fee Related
2013
- 2013-01-31 PH PH12013500208A patent/PH12013500208B1/en unknown
- 2013-05-03 HK HK13105346.5A patent/HK1178437A1/xx not_active IP Right Cessation
- 2013-05-16 HK HK13105845.1A patent/HK1178793A1/xx not_active IP Right Cessation
- 2013-12-18 CY CY20131101143T patent/CY1114808T1/el unknown
2018
- 2018-03-20 US US15/926,637 patent/US20180311328A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0300814A2 (hu)	2003-10-28
WO2002016410A2 (en)	2002-02-28
US8961986B2 (en)	2015-02-24
CN102784385B (zh)	2015-11-25
HK1178437A1 (en)	2013-09-13
BRPI0113400B1 (pt)	2018-05-15
HU230233B1 (hu)	2015-10-28
MXPA03001606A (es)	2004-11-01
US20130156798A1 (en)	2013-06-20
PT1311542E (pt)	2008-10-03
HUP0300814A3 (en)	2005-11-28
CN102764425B (zh)	2015-11-25
EP1918298A3 (en)	2008-05-28
CY1114808T1 (el)	2016-12-14
ES2310558T3 (es)	2009-01-16
SI1918298T1 (sl)	2011-01-31
CY1108558T1 (el)	2014-04-09
US20080200368A1 (en)	2008-08-21
ATE483729T1 (de)	2010-10-15
CA2420949A1 (en)	2002-02-28
HU229377B1 (hu)	2013-11-28
DK1918298T3 (da)	2010-11-29
PH12013500208A1 (en)	2015-04-20
CN101633689A (zh)	2010-01-27
BR0113400A (pt)	2003-07-08
PT1731912E (pt)	2013-12-17
ES2353347T3 (es)	2011-03-01
HK1052359B (zh)	2008-11-14
CN102784385A (zh)	2012-11-21
NZ523841A (en)	2004-07-30
EP1731912B1 (en)	2013-09-25
US8343500B2 (en)	2013-01-01
PH12013500208B1 (en)	2015-04-20
HU229489B1 (hu)	2014-01-28
CZ307202B6 (cs)	2018-03-21
EP1311542A2 (en)	2003-05-21
IL154089A0 (en)	2003-07-31
ATE401343T1 (de)	2008-08-15
US20030191063A1 (en)	2003-10-09
NO20030790L (no)	2003-04-22
PL217929B1 (pl)	2014-09-30
EP1918298B1 (en)	2010-10-06
JP2004506921A (ja)	2004-03-04
NO20030790D0 (no)	2003-02-19
CN102764425A (zh)	2012-11-07
EP1731912A3 (en)	2006-12-27
AU7863701A (en)	2002-03-04
CN1469883A (zh)	2004-01-21
PL213585B1 (pl)	2013-03-29
KR20030062321A (ko)	2003-07-23
PL215145B1 (pl)	2013-10-31
PL399137A1 (pl)	2012-07-30
NO337988B1 (no)	2016-07-18
NO20101441L (no)	2003-04-22
NO330535B1 (no)	2011-05-09
ES2439899T3 (es)	2014-01-27
EP1918298A2 (en)	2008-05-07
PT1918298E (pt)	2010-12-09
CY1111079T1 (el)	2015-06-11
EP1731912A2 (en)	2006-12-13
HK1178793A1 (en)	2013-09-19
CA2420949C (en)	2012-01-03
DE60134862D1 (de)	2008-08-28
WO2002016410A3 (en)	2002-09-12
PL364048A1 (pl)	2004-12-13
US20180311328A1 (en)	2018-11-01
AU2001278637B2 (en)	2006-05-25
DK1731912T3 (da)	2014-01-06
SI1731912T1 (sl)	2014-05-30
EP1311542B1 (en)	2008-07-16
PL215187B1 (pl)	2013-11-29
SI1311542T1 (sl)	2009-02-28
JP5431628B2 (ja)	2014-03-05
CN101633689B (zh)	2013-09-04
DK1311542T3 (da)	2008-11-10
DE60143234D1 (de)	2010-11-18
HK1052359A1 (en)	2003-09-11

Publication	Publication Date	Title
PL399137A1 (pl)	2012-07-30	Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego
AU2002229510A1 (en)	2002-08-19	Combined use of factor vii polypeptides and factor viii polypeptides
BR0007597A (pt)	2001-10-16	Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
CY1110862T1 (el)	2015-06-10	Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
IS2670B (is)	2010-09-15	Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
HUP0401121A2 (hu)	2004-09-28	Csökkentett immunogenitású, módosított trombopoietin (TPO)
HUP0402160A2 (hu)	2005-01-28	T-sejt-epitópok a karboxipeptidáz-G2-ben

Legal Events

Date	Code	Title	Description
2014-02-28	RECP	Rectifications of patent specification